BillionToOneBLLN +2.04%13 Days Payable is 24.74 as of Mar. 2026, which is 15% above its 10-year median of 21.54. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, BillionToOne ranks worse than 83.16% on this metric.
The historical rank and industry rank for BillionToOne's Days Payable or its related term are showing as below:
BLLN'
s Days Payable Range Over the Past 10 Years
Min: 19.14 Med: 21.54 Max: 27.51
Current: 27.51
During the past 3 years, BillionToOne's highest Days Payable was 27.51. The lowest was 19.14. And the median was 21.54.
BLLN's Days Payable is ranked worse than 83.16% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs BLLN: 27.51
BillionToOne's Days Payable
increased
from Mar. 2025 (18.71) to Mar. 2026 (24.74).
It may suggest that BillionToOnedelayed paying its suppliers.
BillionToOne Days Payable Related Terms
BillionToOne Days Payable Historical Data
* Premium members only.
The historical data trend for BillionToOne's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BillionToOne's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's Days Payable distribution charts can be found below:
* The bar in red indicates where BillionToOne's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BillionToOne's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BillionToOne (BLLN) has a Days Payable of 24.74 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BillionToOne and its competitors. This is 15% above median its historical median of 21.54. Over the past decade, BillionToOne's Days Payable has ranged from 19.14 to 27.51. According to the industry distribution chart, BillionToOne ranks #158 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 83.2%.
Is BillionToOne's Days Payable too high?
BillionToOne's current Days Payable of 24.74 is 15% above median its 10-year median of 21.54. Over the past 10 years, this metric has ranged from a low of 19.14 to a high of 27.51. The Medical Diagnostics & Research industry median Days Payable is 67.28. BillionToOne's value of 24.74 is 63.2% below this industry median. Based on the distribution chart, BillionToOne ranks #158 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Days Payable compare to SHC and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #158 out of 190 companies for Days Payable. This places BillionToOne in the lower half of its industry. The industry median Days Payable is 67.28. BillionToOne's value of 24.74 is 63.2% below this benchmark. Historically, BillionToOne's own Days Payable has ranged from 19.14 to 27.51 over the past decade. While the company's 10-year median is 21.54 vs. the industry median of 67.28, BillionToOne has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current Days Payable of 24.74 is 63.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BillionToOne and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current Days Payable is 24.74, which is 15% above median its own 10-year median of 21.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Days Payable of 24.74. The current Days Payable is 24.74, which is 15% above median its 10-year median of 21.54 and 63.2% below the Medical Diagnostics & Research industry median of 67.28. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BillionToOne (BLLN), the current Days Payable is 24.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score
Get the complete analysis for BLLN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 